HRT Patches vs Tablets vs Gels: How the Route Changes Absorption and Risk

A reader wrote to us last month describing her kitchen counter: a foil-backed patch on one side, a tube of gel on the other, and a phone open to a post declaring that one of them was “basically risk-free.” She wanted to know which route was true and which was marketing. As of early 2026, that question is being typed into search engines more than at any point in a decade.

Two things lit the fuse. In late 2025, US regulators announced a review that would soften the sweeping boxed warnings that have sat on menopausal hormone therapy labels since the early 2000s. Around the same time, short videos comparing hrt patches, tablets and gels racked up tens of millions of views, many of them confident and few of them accurate.

The honest story is more interesting than either extreme. The route a hormone takes into the body genuinely changes how it behaves, and the evidence for that is solid in some places and thin in others.

How do HRT patches work, and why does the route matter?

Menopausal hormone therapy, usually shortened to HRT or MHT, replaces some of the estrogen the ovaries stop producing around menopause. The active ingredient in most modern products is estradiol, the same estrogen the body made before menopause. What differs between products is the doorway it uses.

Swallow a tablet and the hormone dissolves in the gut, crosses into the bloodstream that drains the intestines, and arrives at the liver before it reaches anywhere else. Pharmacologists call this first-pass metabolism: the liver processes a drug before it circulates through the body. The liver converts much of the estradiol into a weaker estrogen called estrone, and it responds to the sudden high concentration by ramping up production of several proteins, including some involved in blood clotting.

An hrt patch takes a different door. A thin adhesive reservoir sits on the skin of the lower abdomen or buttock, and estradiol diffuses slowly through the outer skin layers into tiny blood vessels beneath. From there it travels through general circulation and reaches the liver only in the diluted concentration the rest of the body sees. Gels and sprays use the same principle; the hormone dries into the skin and releases over hours.

Three consequences follow. Blood levels from a patch stay relatively flat, while a tablet produces a daily rise and fall. The ratio of estradiol to estrone in the blood stays closer to the premenopausal pattern with transdermal delivery, meaning across the skin. And the liver, spared the concentrated first pass, does not shift its protein output in the same way.

That third point is the heart of the safety debate. According to MedlinePlus and NHS summaries, the symptom relief for hot flashes and night sweats is broadly comparable across routes when the delivered hormone level is similar. The differences that matter are downstream, in how the liver, the clotting system and the blood vessels respond.

What changed recently to put hrt patches back in the news

The modern anxiety about hormone therapy dates to July 2002, when the Women’s Health Initiative, a randomized trial of more than 16,000 postmenopausal women taking an oral estrogen-plus-progestin tablet, was stopped early after investigators saw more breast cancers, strokes and blood clots than expected. Prescriptions collapsed by roughly half within two years. Mayo Clinic’s overview notes that later analyses showed the picture was strongly shaped by age: participants averaged 63 at enrollment, more than a decade past the typical age of menopause.

Between 2015 and 2019, several developments shifted the conversation toward route of delivery. UK national guidance in 2015 stated plainly that transdermal estrogen was not associated with the increased clot risk seen with tablets. In January 2019, a large UK database study published in the BMJ and indexed on PubMed compared clot rates across specific products in more than 80,000 women and found the oral-versus-skin difference held up across preparations.

The NHS updated its public pages on HRT types and on benefits and risks to reflect that evidence, distinguishing oral from transdermal routes in its clot-risk language. Cleveland Clinic and Mayo Clinic now describe the same distinction in their consumer material.

The late-2025 US regulatory announcement, which proposed narrowing the broad boxed warnings on menopausal hormone products, did not change the underlying evidence on route. What it did was send a wave of people back to their search bars. Interest in comparisons of patches, tablets and gels rose sharply, and social platforms filled the gap with content that ranged from careful to cavalier.

Worth stating clearly: no new randomized trial comparing routes head-to-head on hard outcomes has been published. The most recent large evidence remains observational, which is why the sections below spend so much time on how strong each finding really is.

Tablets: what happens when estrogen goes through the liver first

Oral estrogen has the longest track record of any route, and most of what medicine knows about hormone therapy risks, good and bad, comes from tablet studies. That history cuts both ways. Tablets are the best-studied option, and they are also the route in which certain risks were first measured.

When concentrated estrogen reaches the liver, several measurable things happen. Production of clotting factors rises, and levels of proteins that normally restrain clotting fall slightly. C-reactive protein, a marker of inflammation, climbs. Sex hormone-binding globulin, a carrier protein that holds hormones in an inactive state, increases substantially, which can lower the amount of free, active testosterone in circulation. Triglycerides, a type of blood fat, tend to go up.

Not every liver effect is unfavorable. Oral estrogen raises HDL cholesterol, sometimes called the protective cholesterol, more than transdermal estrogen does, and it lowers LDL cholesterol. In the years before the Women’s Health Initiative, these lipid changes were a large part of why clinicians expected hormone therapy to protect the heart.

The Women’s Health Initiative used a tablet containing conjugated equine estrogens, a mixture of estrogens derived from horse urine, combined with a synthetic progestin. Many current tablets instead contain estradiol, which is chemically identical to the human hormone. Whether estradiol tablets behave differently from conjugated estrogens on clot and stroke risk is not fully settled; the 2019 BMJ analysis suggested conjugated estrogens carried a somewhat higher clot risk than oral estradiol, but both oral forms were associated with more clots than transdermal products.

Tablets remain a reasonable, widely used choice, and the Mayo Clinic overview is explicit that for many healthy women within ten years of menopause, benefits can outweigh risks regardless of route. What the liver-first pathway does is add a layer of risk that, for people who already carry clot or stroke risk factors, may tip a clinician’s judgment toward the skin.

HRT patches: steady delivery through the skin

The transdermal patch was developed in the 1980s partly to solve the first-pass problem. A patch holds estradiol in an adhesive matrix or a small reservoir, pressed against skin below the waistline, and releases it at a roughly constant rate for days at a time. Users swap it for a fresh one on a rhythm set by the product and the prescriber.

Because the hormone enters general circulation rather than the gut, blood estradiol levels stay within a narrower band. There is no morning spike and evening trough. For some people this smoother profile means fewer breakthrough symptoms late in the dosing interval; for others it makes no noticeable difference. Trials measuring hot-flash frequency have generally found patches and tablets similarly effective when matched for delivered hormone.

The liver sees estradiol only at the diluted concentration present throughout the body. In laboratory studies, transdermal estrogen produces little or no change in clotting factors, C-reactive protein or sex hormone-binding globulin. Triglycerides stay roughly flat. The favorable HDL rise seen with tablets is smaller.

MedlinePlus lists the practical realities: patches can irritate skin, may loosen with sweat, heat or swimming, and should be rotated among sites to give skin a rest. A patch that repeatedly falls off delivers an unpredictable amount of hormone, which matters more than most people expect. Sunlight and heat sources such as saunas or heating pads can increase how fast hormone moves through the skin.

One underappreciated point: absorption varies between individuals. Skin thickness, body fat distribution and even ambient temperature influence how much estradiol crosses. Two people wearing identical patches can end up with meaningfully different blood levels. That variability is one reason clinicians sometimes check how symptoms respond rather than assuming the label tells the whole story, and it is a decision that belongs with the prescriber.

HRT gel vs patch: same route, different daily experience

Estradiol gel and the newer spray formulations belong to the same transdermal family as patches. The hormone is dissolved in an alcohol-based gel that is rubbed onto the skin of the arm, shoulder or thigh, dries within minutes, and releases into the bloodstream over the following hours. Pharmacologically, the liver-sparing logic is identical to a patch.

Where gels differ is in texture, timing and human behavior. A gel is applied on a routine the prescriber sets, and blood levels rise and fall over the day a little more than with a patch, though far less than with a tablet. There is no adhesive, so skin irritation is uncommon, and there is nothing to fall off in the shower. People who dislike a visible patch or who react to adhesives often find gels easier to live with.

The trade-offs are practical. Gel must dry fully before clothing touches the area, and NHS guidance advises washing hands afterward and avoiding skin-to-skin contact with the application site for a period, because estradiol can transfer to a partner, child or pet. Bathing or heavy sweating soon after application can reduce absorption. Forgetting a daily application is easier than forgetting a patch that stays put.

On outcomes, gels have less dedicated evidence than patches simply because they arrived later and have been prescribed in smaller numbers in the large databases. The 2019 BMJ study grouped transdermal products together and found no increased clot risk across the class. Cleveland Clinic and NHS material treat gels and patches as interchangeable on the clot question, which is a reasonable reading of the mechanism, while acknowledging the gel-specific data are thinner.

Choosing between them is rarely about safety and mostly about skin, lifestyle and adherence. That conversation belongs in the consulting room, where a clinician can weigh how someone actually lives against how each form actually behaves.

Is an HRT patch safer than tablets when it comes to blood clots?

Venous thromboembolism, the medical term for a clot forming in a deep vein and sometimes traveling to the lungs, is the outcome where route makes the clearest difference. It is also the one where the evidence is most consistent.

Start with the baseline. In women in their fifties not taking hormones, deep-vein clots occur at roughly one to two per 1,000 per year. The Women’s Health Initiative found that oral combined therapy approximately doubled that rate. The 2019 BMJ database study, following women in UK general practice, reported that oral hormone therapy was associated with about a 60 to 70 percent higher clot risk overall, translating to roughly nine extra clots per 10,000 women per year. Transdermal estrogen, by contrast, showed no statistically significant increase.

That pattern has now appeared in a French cohort, a Danish registry, several case-control studies and a meta-analysis pooling them. Consistency across countries, databases and study designs strengthens the finding considerably. The mechanism fits: the liver-driven rise in clotting factors seen with tablets simply does not occur when estrogen bypasses the first pass.

Here is the caveat that the confident videos skip. All of this is observational. Women prescribed patches may differ from women prescribed tablets in ways that databases cannot fully capture; clinicians may already steer higher-risk patients toward the skin, which would make transdermal users look artificially safer. No large randomized trial has assigned women to patch versus tablet and counted clots. The observational evidence is strong, biologically plausible and repeatedly replicated, but it sits one rung below trial evidence.

What this means in practice, according to NHS and Mayo Clinic guidance, is that for someone with clot risk factors such as obesity, a previous clot or a family history of clotting disorders, a clinician will often lean toward a transdermal route. For someone at low baseline risk, the absolute difference is small either way. The decision rests with the prescribing clinician.

Stroke and heart health: does the route change cardiovascular risk?

Stroke is a more complicated story than clots, and the evidence is weaker. The Women’s Health Initiative reported about eight extra strokes per 10,000 women per year on oral combined therapy, and a similar increase in the estrogen-only arm. Those were tablet studies in women averaging 63 years old, so two variables, route and age, are tangled together.

Observational work has tried to separate them. A UK database analysis published in 2010 found that transdermal estrogen was not associated with increased stroke risk, while oral estrogen was, though the difference depended partly on how much hormone was delivered. Later cohort studies have been broadly consistent but not unanimous. The American Heart Association’s position is that hormone therapy should not be used to prevent cardiovascular disease, and that statement applies regardless of route.

On heart disease itself, the emerging picture concerns timing more than route. Analyses of the Women’s Health Initiative and other trials suggest that women who begin hormone therapy within about ten years of menopause, or before age 60, do not show the increase in coronary events seen in older starters, and some analyses hint at a modest reduction. Whether patches offer additional cardiovascular advantage over tablets in this younger group has not been tested in a trial designed to answer it.

Blood pressure offers a small, concrete difference. Oral estrogen can raise blood pressure slightly in some women through liver-mediated effects on the renin system, which regulates fluid and vessel tone. Transdermal estrogen appears neutral or mildly favorable. For someone with hypertension, that is one factor among several that a clinician may consider.

The fair summary: route probably matters for stroke, likely through the same clotting and inflammatory pathways that matter for venous clots, but the evidence is observational and less consistent than for venous clots. For heart disease, the strongest signal is when therapy starts, not how it enters the body.

Breast cancer risk: does patch, tablet or gel make a difference?

This is the risk most people fear, and it is the one where route appears to matter least. The evidence points instead at two other variables: whether a progestogen is included, and for how long therapy continues.

The Women’s Health Initiative found that oral estrogen plus a synthetic progestin increased breast cancer diagnoses after about five years of use. Its estrogen-only arm, in women who had undergone hysterectomy, did not show an increase over the trial period, and longer follow-up suggested a reduction. A 2019 pooled analysis of 58 studies in the Lancet, covering more than 100,000 women with breast cancer, confirmed that combined therapy carried more risk than estrogen alone and that risk grew with duration.

The NHS translates this into absolute terms: for women in their fifties, roughly 23 in every 1,000 will be diagnosed with breast cancer over five years without hormone therapy; combined HRT adds around five cases per 1,000 over that period, and estrogen-only therapy adds fewer. These are modest increases against a meaningful background rate.

Crucially, the Lancet analysis found no material difference between oral and transdermal estrogen. Once estrogen is in the bloodstream, breast tissue responds to it regardless of the door it came through. Where a difference may exist is in the type of progestogen: observational data suggest micronized progesterone, which is chemically identical to the body’s own progesterone, may carry less breast risk than some synthetic progestins. That finding is observational and not yet confirmed by trials.

Breast cancer risk is one reason routine screening matters. In the US, mammography is generally recommended every two years from age 40; in the UK, the NHS program invites women from around age 50. Anyone on hormone therapy should follow the screening schedule their clinician recommends, and questions about personal risk belong in that conversation rather than in a symptom checklist.

The progestogen question: the part of HRT that the route debate often skips

Anyone with a uterus who takes estrogen also needs a progestogen, the general term for progesterone or the synthetic hormones that mimic it. Estrogen on its own thickens the uterine lining, and unopposed thickening raises the risk of endometrial cancer several-fold. A progestogen keeps the lining in check. Women who have had a hysterectomy usually take estrogen alone.

This matters for the route debate because the estrogen route and the progestogen route are often different. Some patches combine estradiol with a progestogen in a single adhesive. More commonly, a person uses an estradiol patch or gel and takes the progestogen separately, either as a capsule of micronized progesterone or via a hormone-releasing intrauterine device that delivers progestogen directly to the uterine lining.

Each combination has its own profile. Micronized progesterone, taken by mouth, is metabolized into compounds that many people find mildly sedating, which is why it is often taken at night. The intrauterine route delivers progestogen locally with very little reaching the bloodstream, and it doubles as contraception for women in perimenopause who still need it. Synthetic progestins in combined tablets and patches vary in how they affect mood, fluid retention and, as noted above, possibly breast tissue.

The 2019 BMJ clot study found that the type of progestogen also influenced risk within oral products: some synthetic progestins were associated with more clots than others, while micronized progesterone appeared neutral. This is an observational finding, but it reinforces a point that viral content misses entirely. Comparing “the patch” to “the pill” is incomplete unless you also ask what progestogen is in the picture and how it is delivered.

Bleeding patterns depend on the progestogen schedule too. Cyclical regimens produce a predictable monthly bleed; continuous regimens aim for no bleeding after an initial settling period. Any unexpected bleeding on either pattern is a reason to see the prescriber, covered in detail below.

What the evidence actually says, and how strong it is

Medical evidence comes in grades. Randomized trials, where participants are assigned by chance to one treatment or another, sit at the top because they minimize hidden differences between groups. Observational studies, which follow people who chose or were prescribed a treatment, sit below because those choices can be influenced by the very risks under study. Expert opinion and mechanistic reasoning sit lower still. Here is how the route evidence stacks up.

Symptom relief across routes: supported by randomized trials. Head-to-head trials measuring hot-flash frequency have found patches, gels and tablets broadly equivalent when delivered hormone levels are matched. High confidence.

Venous clot risk lower with transdermal estrogen: supported by multiple large observational studies in several countries plus a coherent mechanism confirmed in laboratory measurements of clotting factors. No randomized trial has tested it directly. Moderate-to-high confidence, with the standard observational caveat that prescribing patterns could exaggerate the difference.

Stroke risk lower with transdermal estrogen: supported by fewer observational studies with less consistent results. Low-to-moderate confidence.

Breast cancer risk similar across routes: supported by a very large pooled analysis of observational data and consistent with mechanism. Moderate confidence that route is not a major factor; the progestogen type and duration findings are also observational.

Cardiovascular benefit with earlier initiation: supported by post-hoc analyses of randomized trials and by observational cohorts. Post-hoc means analyzed after the fact rather than as the trial’s original question, which weakens it. Moderate confidence on timing; low confidence on any route-specific heart benefit.

Blood pressure neutrality with transdermal estrogen: supported by small trials and mechanistic studies. Moderate confidence for a small effect.

Mayo Clinic’s overview, the NHS risk pages and Cleveland Clinic’s summary all reflect this hierarchy: confident on symptom relief, fairly confident on clots, more tentative elsewhere. A reader who remembers only one thing should remember that the clot finding is the sturdiest route-specific result, and even it rests on observational ground.

Patches vs tablets vs gels at a glance

The table below pulls together the practical and evidence-based differences discussed so far. It describes typical patterns reported in mainstream sources; individual responses vary, and none of these rows substitutes for a prescriber’s assessment of personal history.

Feature	Tablets (oral)	Patches (transdermal)	Gels and sprays (transdermal)
Path into the body	Gut, then liver first pass, then circulation	Skin directly into circulation	Skin directly into circulation
Blood hormone pattern	Daily peak and trough	Steady over several days	Mild daily rise and fall
Estradiol-to-estrone ratio	Shifted toward estrone	Closer to premenopausal	Closer to premenopausal
Clotting factors and CRP	Increased	Little or no change	Little or no change
Venous clot risk (observational)	Roughly 1.6 to 2 times baseline	No significant increase	No significant increase
Stroke risk (observational)	Modest increase in older starters	Possibly no increase; less consistent data	Grouped with patches; limited data
Breast cancer risk	Depends on progestogen and duration	Same as tablets for a given regimen	Same as tablets for a given regimen
Triglycerides	Tend to rise	Roughly neutral	Roughly neutral
HDL cholesterol	Larger rise	Smaller rise	Smaller rise
Blood pressure	May rise slightly in some	Neutral	Neutral
Common local effects	Nausea, bloating in some	Skin irritation, adhesive failure	Transfer to others if not dried; alcohol smell
Effect of heat, sweat, water	None	Can loosen or speed absorption	Can reduce absorption if washed early
Depth of long-term outcome data	Largest, including randomized trials	Large observational	Smaller observational

Two rows deserve emphasis. The clot row is where the routes genuinely diverge in the evidence. The breast cancer row is where they do not, and where the columns to look at are the progestogen and the calendar, not the delivery form. Everything else is a matter of degree, preference and the specific risk profile sitting in the exam chair.

HRT patch side effects and the everyday trade-offs of each route

Most side effects of hormone therapy come from the hormone rather than the route: breast tenderness, bloating, headaches, mood shifts and irregular bleeding in the first months are reported across patches, tablets and gels alike. Mayo Clinic notes that many of these settle within a few months as the body adjusts. A handful of effects are route-specific and worth knowing about.

Patches most often cause skin reactions. Redness, itching or a rectangular outline where the adhesive sat are common, especially in warm weather. Rotating sites and letting a used spot rest before reuse helps. Some people react to the adhesive itself rather than the hormone, in which case a different brand or a switch to gel is something a clinician might suggest. Patches also have a habit of lifting at the edges after swimming, saunas or vigorous exercise; a partly detached patch delivers an unreliable amount and is a legitimate reason to raise the issue with the prescriber rather than improvise.

Gels carry the transfer risk described earlier. A partner who repeatedly touches freshly applied gel can absorb estradiol; children and pets are more vulnerable because of smaller body size. Letting the gel dry completely, covering the area with clothing and washing hands are the standard precautions NHS guidance describes. The alcohol base can sting on broken skin and has a noticeable smell for a minute or two.

Tablets sidestep skin issues entirely but are more likely to cause nausea, and their effect on triglycerides and gallbladder function is relevant to some people. Oral estrogen is associated with a higher rate of gallstones and gallbladder disease than transdermal estrogen in observational studies, another liver-related difference.

Liver effects also change how oral estrogen interacts with other medicines. Drugs that speed up or slow down liver enzymes can alter tablet estrogen levels more than patch or gel levels. Anyone taking thyroid hormone, certain seizure medicines or some antibiotics should mention this to whoever prescribes their hormone therapy, since it may influence which route makes sense.

Why clinicians steer some people toward the skin and others toward tablets

Guidance from the NHS, Mayo Clinic and Cleveland Clinic converges on a general principle: for someone at low baseline risk, any route is acceptable and preference should lead. For someone carrying specific risk factors, the transdermal route is often favored because it avoids the liver-driven effects described above. The list of circumstances where that tilt tends to happen is fairly consistent across sources.

A personal or family history of venous clots, or a known clotting disorder, is the clearest example. Obesity, which independently raises clot risk, is another. Migraine with aura, in which visual or sensory disturbances precede the headache, is associated with a higher stroke risk, and transdermal estrogen’s flatter blood levels and neutral clotting profile make it the usual preference in that group. Hypertension that is controlled but present, elevated triglycerides, gallbladder disease and some liver conditions all nudge toward the skin for the same mechanistic reasons.

Conditions affecting the gut can matter too. People with malabsorption disorders or those who have had certain weight-loss surgeries may absorb oral hormones unpredictably, which makes a transdermal route more reliable. Smokers over 35 face compounded cardiovascular risk from oral estrogen, though the more important conversation there is about the smoking.

The tilt is not always toward the skin. Someone with a skin condition that makes adhesives or alcohol-based gels intolerable, or whose work or climate makes patches impractical, may do better with a tablet. People who have struggled to remember daily applications sometimes prefer a patch that stays on for days, or a tablet folded into an existing pill routine. Cost and insurance coverage vary and are a legitimate part of the conversation, though not one this article addresses.

None of this constitutes a rule. It describes how experienced prescribers tend to reason, and it is offered so readers can understand the questions being asked of them. The final weighing of history, preference and evidence belongs to the clinician and the person in front of them.

Common myths about HRT patches, tablets and gels

The viral wave that sent people searching this topic carried a few claims that deserve a calm correction. Each contains a grain of truth wrapped in a layer of exaggeration.

Myth: patches carry zero risk. The observational evidence shows no increase in venous clot risk with transdermal estrogen, which is genuinely reassuring. It does not show zero risk of anything. Breast cancer risk with a combined regimen is essentially the same whether the estrogen arrives by patch or tablet. Stroke data are less consistent than clot data. And observational evidence, however replicated, cannot fully rule out that prescribers already send higher-risk people toward patches, flattering the comparison.

Myth: gels are natural and tablets are synthetic. Estradiol in a gel, a patch and most modern tablets is the same molecule, chemically identical to the hormone the ovaries once made. The word “natural” in marketing often refers to the manufacturing origin, typically plant sterols, not to how the body experiences it. The more meaningful distinction is between estradiol products and conjugated equine estrogens, and even that is a question of molecule, not route.

Myth: tablets are dangerous and outdated. Tablets remain the most thoroughly studied form of hormone therapy and are appropriate for many people. Their additional clot risk is real but small in absolute terms for someone at low baseline risk.

Myth: the 2025 labeling review means hormone therapy is now proven safe. A regulatory decision to narrow warnings reflects a re-reading of existing evidence about age and timing. It did not produce new data and did not change the route findings described here.

Myth: compounded bioidentical hormones are safer than regulated products. Compounded hormones are mixed by individual pharmacies and are not approved by regulators for safety or consistency. Mainstream sources including Mayo Clinic and Cleveland Clinic advise that regulated estradiol products, which are also bioidentical, have the evidence base. Compounded products are not a self-treatment option and questions about them belong with a clinician.

When to see a doctor about HRT, whatever the route

Hormone therapy is a prescribed treatment, and every decision about starting, changing route, adjusting or stopping it belongs with the clinician who prescribes it. Stopping abruptly on the strength of a video or a headline can bring symptoms back sharply and removes the chance to make a considered change. That said, some situations call for prompt contact rather than waiting for the next scheduled review.

Seek urgent medical attention, calling emergency services if necessary, for any of the following while using estrogen by any route: sudden pain, swelling, warmth or redness in one leg; sudden chest pain, breathlessness or coughing up blood, which can signal a clot in the lungs; sudden weakness or numbness on one side of the body, facial drooping, trouble speaking or a sudden severe headache unlike previous headaches, which can signal a stroke; sudden loss of vision or double vision; or severe abdominal pain with yellowing of the skin or eyes.

Contact the prescriber soon, without waiting for a routine appointment, for: vaginal bleeding that is unexpected on a continuous regimen, heavier or more prolonged than usual on a cyclical regimen, or that returns after having stopped; a new breast lump, nipple discharge or skin change on the breast; migraine that develops aura for the first time or changes character; a patch site that is blistering or spreading beyond the adhesive edge; or new or worsening high blood pressure readings.

Raise at the next routine review: hot flashes or night sweats returning before the end of a dosing interval; mood changes, persistent bloating or breast tenderness that have not settled after the first few months; patches repeatedly failing to stick; or a partner or child who may be having skin contact with gel.

Mainstream guidance recommends reviewing hormone therapy with a clinician at least annually to reassess symptoms, risk factors and whether the current route and regimen still fit. That review, not a search result, is where the patch-versus-tablet-versus-gel question gets properly answered for any individual.

Frequently asked questions

Is an HRT patch safer than tablets?

For blood clots, observational evidence consistently shows patches carry less risk than tablets because they bypass the liver’s first-pass effect on clotting factors. For breast cancer, the route makes little difference. For stroke, data lean toward patches but are less consistent. Whether that adds up to “safer” for a specific person depends on their own risk factors, which is why the choice belongs with the prescribing clinician.

How do HRT patches work?

A patch holds estradiol in an adhesive layer pressed against the skin, usually on the lower abdomen or buttock. The hormone diffuses slowly through the outer skin into small blood vessels and then into general circulation, producing relatively steady blood levels for days. Because it avoids the gut and liver first pass, it does not trigger the rise in clotting proteins seen with tablets.

What are the most common HRT patch side effects?

Skin redness, itching or a rectangular mark where the adhesive sat are the most route-specific effects, along with patches loosening after swimming, sweating or heat. Hormone-related effects such as breast tenderness, bloating, headache and irregular bleeding in early months are shared with tablets and gels and often settle over time. Blistering or spreading skin reactions warrant a call to the prescriber.

HRT gel vs patch: which is better?

Neither is better on safety; both are transdermal and share the liver-sparing profile. The difference is practical. Patches stay on for days and suit people who forget daily routines, but can irritate skin or fall off. Gels avoid adhesives and skin marks but must dry fully, can transfer to others through contact, and require a daily habit. Preference, skin and lifestyle usually decide.

Does the route of HRT affect breast cancer risk?

Current evidence says no. A 2019 pooled analysis of 58 studies found no material difference between oral and transdermal estrogen on breast cancer risk. Risk instead rises with the inclusion of a progestogen and with longer duration of use. Some observational data suggest micronized progesterone may carry less risk than certain synthetic progestins, though this is not confirmed by randomized trials.

Why does oral estrogen increase clot risk more than a patch?

When estrogen is swallowed, it reaches the liver in high concentration before circulating through the body. The liver responds by producing more clotting factors and less of the proteins that restrain clotting, along with more inflammatory markers. Transdermal estrogen reaches the liver only at the diluted level found throughout the body, so these shifts are minimal. Laboratory measurements confirm the difference.

Can I switch from HRT tablets to a patch on my own?

No. Changing route alters how much hormone reaches the bloodstream and how steadily, and it can affect bleeding patterns and symptom control. It may also change how the estrogen interacts with other medicines. Any switch should be planned with the prescribing clinician, who can review your risk factors, choose an appropriate product and arrange follow-up to check how you respond.

Do HRT patches affect cholesterol and blood pressure differently from tablets?

Yes, modestly. Oral estrogen raises HDL cholesterol more but also tends to raise triglycerides and can nudge blood pressure upward in some people through liver-mediated effects. Transdermal estrogen has a smaller HDL effect, leaves triglycerides roughly unchanged and appears neutral on blood pressure. These differences are one reason clinicians may favor patches or gels in people with hypertension or high triglycerides.

Are compounded bioidentical hormones safer than HRT patches?

There is no evidence they are safer, and they lack regulatory approval for safety, purity and consistent dosing. Regulated estradiol patches, gels and tablets are themselves bioidentical, meaning chemically identical to the body’s hormone, and have the evidence base behind them. Compounded products are not appropriate for self-treatment; any questions about them should be raised with a clinician.

What changed in 2025 regarding HRT warnings?

US regulators announced a review aimed at narrowing the broad boxed warnings that have appeared on menopausal hormone products since the Women’s Health Initiative results in 2002, reflecting later analyses showing risks depend heavily on age and timing of use. The review did not produce new trial data and did not alter the evidence comparing patches, tablets and gels. It did drive a surge in public interest.

References

• NHS — Types of hormone replacement therapy (HRT)
• NHS — Benefits and risks of hormone replacement therapy (HRT)
• Cleveland Clinic — Hormone Therapy for Menopause Symptoms
• MedlinePlus — Estradiol Transdermal

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.